The Outcomes-Based Reimbursement Experiment

US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.

Value-based reimbursement contracts between pharmaceutical manufacturers and US payers appear to be gaining momentum, with several such contracts signed in the last year. But while tying the cost of a drug to the value it delivers appeals to both payers and drug manufacturers, regulatory roadblocks and execution challenges will limit their adoption in the near term. Their viability long-term will probably depend on the savings they deliver to the US healthcare system.

The shift towards outcomes-based reimbursement is in some ways a middle ground for insurers and drug companies. The insurer is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

24 Jul 2025

• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.